Improvement of fibrin clot structure after factor VIII injection in haemophilia A patients treated on demand

Thrombosis and Haemostasis

Volumn 111, Issue 4, 2013, Pages 656-661

  Antovic, Aleksandra ^a   Mikovic, Danijela ^b   Elezovic, Ivo ^c   Zabczyk, Michael ^a,d   Hutenby, Kjell ^a   Antovic, Jovan P ^a,e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Blood Transfusion Institute of Serbia   (Serbia)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Fibrin clot structure; FVIII; Haemophilia A; Scanning electron microscopy

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 12; FIBRIN; FIBRINOGEN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FIBRIN CLOT; HEMOPHILIA A; HEMOSTASIS; HUMAN; MALE; PERMEABILITY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SCHOOL CHILD; AGED; BLOOD; BLOOD CLOTTING; CHEMICAL STRUCTURE; DRUG EFFECTS; GENETICS; METABOLISM; MIDDLE AGED; POROSITY; ULTRASTRUCTURE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD COAGULATION; CARBOXYPEPTIDASE B2; FACTOR XII; FIBRIN; FIBRINOGEN; HEMOPHILIA A; HEMOSTASIS; HUMANS; MICROSCOPY, ELECTRON, SCANNING; MIDDLE AGED; MOLECULAR STRUCTURE; POROSITY; YOUNG ADULT;

EID: 84897564955     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-06-0479     Document Type: Article

References (23)

1. Dargaud Y, Beguin S, Lienhart A, et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93: 475-480.
2. Ramström G, Blombäck M, Egberg N, et al. Oral surgery in patients with hereditary bleeding disorders. A survey of treatment in the Stockholm area (1974-1985). Int J Oral Maxillofac Surg 1989; 18: 320-322.
3. Blanchette VS, Manco-Johnson M, Santagostino E, et al. Optimizing factor prophylaxis for the haemophilia population: where do we stand? Haemophilia 2004; 10 (Suppl 4): 97-104.
4. Blomback B, Carlsson K, Fatah K, et al. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-538.
5. Rainsford SG, Hall A. A three-year study of adolescent boys suffering from haemophilia and allied disorders. Br J Haematol 1973; 24: 539-551.
6. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-399.
7. Wolberg AS, Allen GA, Monroe DM, et al. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol 2005; 131: 645-655.
8. He S, Blombäck M, Jacobsson Ekman G, et al. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 2003; 1: 1215-1219.
9. Dargaud Y, Prevost C, Lienhart A, et al. Evaluation of the overall haemostatic effect of recombinant factor VIIa by measuring thrombin generation and stability of fibrin clots. Haemophilia 2011; 17: 957-961.
10. Brummel-Ziedins KE, Branda RF, Butenas S, Mann KG. Discordant fibrin formation in haemophilia. J Thromb Haemost 2009; 7: 825-832.
11. Antovic JP, Mikovic D, Elezovic I, et al. Two global haemostatic assays as additional tools to monitor treatment in cases of Haemophilia A. Thromb Haemost 2012; 108: 21-31.
12. Blomback B, Carlsson K, Hessel B, et al. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 1989; 997: 96-110.
13. He S, Cao H, Antovic A, et al. Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials. Blood Coagul Fibrinolysis 2005; 16: 61-67.
14. Berntorp E, Björkman S. The pharmacokinetics of clotting factor therapy. Haemophilia 2003; 9: 353-359.
15. Carr ME, Jr., Shen LL, Hermans J. Mass-length ratio of fibrin fibres from gel permeation and light scattering. Biopolymers 1977; 16: 1-15.
16. Dey S. A new rapid air-drying technique for scanning electron microscopy using tetramethylsilane: application to mammalian tissue. Cytobios 1993; 73: 17-23.
17. Weibel E. Stereological methods: Practical methods for biological morphometry, vol 1. Academic Press 1979, London, pp. 91-100.
18. Mikovic D, Woodhams BJ, Holmström M, et al. On-demand but not prophylactic treatment with FVIII concentrate increases thrombin activatable fibrinolysis inhibitor activation in severe haemophilia A patients. Int J Lab Hematol 2012; 34: 35-40.
19. Antovic A. The Overall Haemostasis Potential (OHP): a laboratory tool for the investigation of global haemostasis. Semin Thromb Haemost 2010; 36: 772-779.
20. Hyas AM, Sorensen HT, Norengaard L, et al. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe haemophilia A. J Thromb Haemost 2007; 5: 2408-2414.
21. Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Rev 2003; 17 (Suppl 1): S1-5.
22. Blomback B, Hessel B, Hogg D, et al. A two-step fibrinogen--fibrin transition in blood coagulation. Nature 1978; 275: 501-505.
23. Hantgan RR, Hermans J. Assembly of fibrin. A light scattering study. J Biol Chem 1979; 254: 11272-11281.